window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

biomanufacturing

  • Biologics & Biosimilars,Biomanufacturing,CDMOs & Manufacturing,European biotech,Pharmaceuticals and therapeutics

    Cytovance Biologics celebrates 20 years advancing biopharma manufacturing in Oklahoma City

    Cytovance Biologics, a contract development and manufacturing organisation serving the [...]

    November 14, 2025
  • Biomanufacturing,Biotech,CDMOs & Manufacturing,Cell & Gene Therapy,Pharmaceuticals and therapeutics

    BBG Advanced Therapies and CELLforCURE partner to provide transatlantic ATMP manufacturing solutions

    BBG Advanced Therapies (BBGAT), a subsidiary of BioBridge Global and [...]

    October 7, 2025
  • Cell & Gene Therapy,Clinical Development,Pharmaceuticals and therapeutics,Supply Chain & Logistics

    Vitalant launches national service hubs to expand patient access to cell and gene therapies

    Vitalant has launched a national hub-and-spoke model to expand patient [...]

    October 6, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Partnerships & Funding,Pharmaceuticals and therapeutics,Technology and platforms

    eXmoor Pharma and Siam Bioscience partner to expand cell and gene therapy services in Southeast Asia

    eXmoor Pharma and Siam Bioscience have announced a strategic partnership [...]

    September 23, 2025
  • Cell & Gene Therapy,Medical devices,Movers & Shakers,Partnerships & Funding,Pharmaceuticals and therapeutics,Technology and platforms

    Robots could slash cost of cell therapy by 74%, opening doors to wider access

    Multiply Labs and Universal Robots pioneer automated manufacturing for personalised [...]

    August 25, 2025
  • Artificial Intelligence,Biologics & Biosimilars,CDMOs & Manufacturing,Partnerships & Funding,Research & Development,Technology and platforms

    AI-powered bioreactor project aims to transform biologics manufacturing

    A Canada–UK collaboration is developing an AI-driven bioreactor platform designed [...]

    July 25, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Cell & Gene Therapy,Market Access & Commercialization

    Lonza upgrades CDMO outlook following strong H1 2025 performance

    Lonza has raised its full-year 2025 guidance for its contract [...]

    July 25, 2025
  • Artificial Intelligence,Cell & Gene Therapy,Partnerships & Funding,Patient Centricity

    Cellino and Karis Bio join forces to deliver personalized cell therapy in Asia-Pacific

    Cellino and Karis Bio have announced a strategic partnership to [...]

    June 2, 2025
  • Movers & Shakers

    New CEO to supercharge US expansion: Clean Biologics hires life sciences heavyweight

    Clean Biologics has appointed Laurent Claisse as chief executive officer, [...]

    May 12, 2025
  • Biologics & Biosimilars,Cell & Gene Therapy

    Astraveus teams up with NecstGen to trial benchtop CAR-T manufacturing platform

    May 6, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top